Possible Link between History of Hypersensitivity to a Specific Non-steroidal Anti-inflammatory Drug (NSAID) and Positive Results Following Challenge Test to Alternative NSAIDs

Abstract

Introduction:

In subjects with hypersensitivity reactions to non-steroidal anti-inflammatory drugs (NSAIDs), the choice of suitable alternative drugs with the lowest risk of reaction is imperative for therapeutic management. A safe method to exclude drug hypersensitivity is to perform a challenge test for an alternative drug.

The present study was conducted to:

• obtain more information about the safety of NSAIDs;

• assess the risk of reaction following the administration of a selective or nonselective cyclooxygenase 2 (COX-2) inhibitor in patients with a history of adverse reactions to NSAIDs;

• investigate if age and/or gender play a role in the susceptibility to develop adverse reactions to NSAIDs.

Patients and methods:

This retrospective study includes 524 patients with a history of hypersensitivity to NSAIDs admitted to undergo challenge test to an alternative anti-inflammatory drug. Statistical significance was achieved when odds ratio (OR) and risk ratio (RR) values were >1.

Results:

8.39% of patients with hypersensitivity reactions to NSAIDs showed a positive challenge test for the alternative drug. Challenge tests for nonselective COX-2 inhibitors were positive in 16.2% of patients with previous reaction to a same drug class and in 12.9% of patients with a history of reaction to selective COX-2 inhibitors. No positive challenge test to a non-selective COX-2 inhibitor was found in patients with a history of hypersensitivity to nimesulide (CAS 51803-78-2). Challenge tests for selective COX-2 inhibitors were positive in 4.6% of patients with a previous reaction to nonselective COX-2 inhibitors and in 7.2% of patients with a history of reaction to selective COX-2 inhibitors. The RR of a positive challenge test to a non-selective COX-2 inhibitor was significant in patients who had a history of reaction to an analogous compound (P 0.21, OR 1.31, RR 1.26).

Discussion:

In this study, selective COX-2 inhibitors represented the class of NSAIDs less frequently reported as responsible of adverse reaction. These data underline that there is a higher risk to find a positive challenge test to a non-selective COX-2 inhibitor than to a selective one in patients with previous adverse reactions to a non-selective COX-2 inhibitor. Moreover, the data evidence that females could have a higher risk compared to males to develop an adverse reaction to selective COX-2 inhibitors.

In conclusion, it appears necessary to pay attention to the kind of NSAIDs reported as the cause of hypersensitivity in anamnesis, because it must be considered a successful guide in choosing the alternative drug to administer to the patient during the challenge test.

Key words

Challenge test - COX-2 inhibitor - Hypersensitivity - Non-steroidal antiinflammatory drugs

• Literature

• 1 Johansson SGO, O’B HourihaneJ 2, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T et al Position paper. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy. 2001; (56) 813-24
• 2 Thien FC. Drug hypersensitivity. Med J Aust. 2006; Sep 18 185 (6) 333-8
• 3 Guglielmi L, Demoly P. Drug hypersensitivity:epidemiol-ogy and risk factors. Curr Pharm Des. 2006; 12: 3309-12
• 4 Ortolani C, D’Amato G, Giannetti A, Marone G, Moscato G, Meneghini A. Memorandum SIAIC about drug allergy/intolerance. Ital J Allergy Clin Immunol. 1998; 8: 568-95
• 5 Smith WL, DeWitt DL. Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin Nephrol. 1995; 15: 179-94
• 6 Magnan A. Allergy to non steroidal anti-inflammatory drugs. Rev Mal Respir. 2006; 23: 10S66-10S69
• 7 Capone ML, Tacconelli S. Pharmacodinamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat. 2007; 82: 85-94
• 8 Rainsford KD, Members of the Consensus Report Group on Nimesulide. Nimesulide-a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin. 2006; 22: 1161-70
• 9 Namazy JA, Simon RA. Sensitivity to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol. 2002; 89: 542-50
• 10 Inomata N, Osuna H, Yamaguchi J, Onoda M, Takeshita Y, Chiba Y et al Safety of selective cyclooxygenase-2 inhibitors and a basic non-steroidal anti-inflammatory drug (NSAID) in Japanese patients with NSAID-induced urticaria and/or angioedema: comparison of meloxicam, etodolac, tiaramide. J Dermatol. 2007; 34: 172-7
• 11 Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the higly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib. Ann Allergy Asthma Immunol. 2005; 94: 34-8
• 12 Quiralte J. Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. Ann Allergy Asthma Immunol. 2002; 89: 63-6
• 13 Liccardi G, D’Amato G, Canonica GW, Lobefalo G, Noschese P, Piccolo A et al Safety of celecoxib in patients with adverse reactions to nimesulide. Allergy. 2005; 60: 708-9
• 14 Jensen-Jaromil E, Untersmayr E. Gender-medicine aspects in allergology. Allergy. 2008; 63: 610-5